References
  1. Casadevall A and Pirofski LA. “The convalescent sera option for containing COVID-19”. Journal of Clinical Investigation 130 (2020): 1545-1548.
  2. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. JAMA 323 (2020): 1061-1069.
  3. McGonagle D., et al. “Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome”. Autoimmunity Review 19.6 (2020): 102537.
  4. Carod-Artal FJ (2020) Neurological Complications of Coronavirus and COVID-19. Rev Neurol 70: 311-322.
  5. Long B, Brady WJ, Koyfman A, Gottlieb M (2020) Cardiovascular Complications in COVID-19. Am J Emerg Med S0735-6757(20)30277-1.
  6. Kyriakidis N, López-Cortés A, González E, Grimaldos A, Prado E. SARS-CoV-2 vaccines strategies: Acomprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1). Page 6/11.
  7. Incidence of Bell Palsy in Patients With COVID-19. Akina Tamaki, MD1,2; Claudia I. Cabrera, MD, MS1,2; Shawn Li, MD1,2; et alCyrus Rabbani, MD1,2; Jason E. Thuener, MD1,2; Rod P. Rezaee, MD1,2; Nicole Fowler, MD1, 2.JAMA Otolaryngol HeadNeck Surg. 2021;147(8):767-768.
  8. Wan EYF Chui CSL Lai FTT et al. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2021; (published online Aug 16.) https://doi.org/10.1016/S1473-3099(21)00451-5
  9. Cirillo N Doan R. Bell’s palsy and SARS-CoV-2 vaccines—an unfolding story. Lancet Infect Dis. 2021; (published online June 7.)https://doi.org/10.1016/S1473-3099(21)00273-5